Pantoprazol Apharma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Apharma, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to manage acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazol Apharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Apharma is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive gastritis and duodenal ulcers: accelerates ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine disorder.

Pantoprazol Apharma may cause adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea with abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle weakness, irregular heartbeat. - Bone fractures: increased risk with long‑term use, especially in the elderly. - Liver enzyme elevation: signs of hepatic stress in laboratory tests. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy with Pantoprazol Apharma, consider the following precautions: - Assess renal function: dose adjustment may be required in severe kidney impairment. - Evaluate hepatic status: monitor liver enzymes in patients with liver disease. - Review long‑term use: consider bone health assessment for patients on prolonged therapy. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Drug interactions: check concomitant medications that may affect acid suppression or metabolism. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in the original packaging.

Pantoprazol Apharma can affect the pharmacokinetics of several co‑administered medicines. Awareness of these interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): markedly decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, potentially increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring more frequent monitoring. - Methotrexate: increased serum levels, especially at high doses. - Digoxin: modest rise in serum concentration, monitor for toxicity.